Element Biosciences, where courage meets possibility
We’re passionate about building new and differentiated technologies that will disrupt the genomics industry. We pursue rigorous science that supports data-driven decisions in ever-evolving markets. We take risks to challenge the status quo. We celebrate our successes and learn from our failures. We’re committed to empowering customers with unprecedented freedom to study biology.
Exciting team news at Element. We are thrilled to announce the appointments of Jeff Journey as Chief Commercial Officer, David Melaugh as General Counsel, and Jeff Labbadia as VP of Operations.
Every element of a DNA sequencer – reimagined.
Genetic sequencing has become an increasingly powerful tool to understand biology and improve human life. Element Biosciences is creating a brand-new DNA sequencing platform to meet diverse and ever-changing needs in this dynamic market.
Element Biosciences Raises $80M in Series B Financing to Accelerate Development of a New DNA Sequencing Platform
SAN DIEGO, Calif. — Element Biosciences today announced the close of a Series B financing round of $80.3 million, with participation from new investors Fidelity Management & Research Company and JS Capital LLC, as well as existing investors Foresite Capital and Venrock. To date, the company has raised a total of more than $100 million. Proceeds from the financing will be used to accelerate the development of high-quality, low-cost, and easy-to-use genomic sequencing solutions.